VaxThera and Codagenix team up to develop the world’s first fully synthetic yellow fever vaccine for modern cell‑culture production
Executive summary: VaxThera and Codagenix entered a partnership to advance Syn17D‑YF, the world’s first fully synthetic yellow fever vaccine candidate, using modern cell‑culture manufacturing. The vaccine could offer a scalable, egg‑independent production process, strengthening global preparedness for yellow fever outbreaks and addressing current supply constraints.
Who is involved: VaxThera S.A.S. (Colombian biotechnology firm) and Codagenix (U.S. synthetic‑biology company).
Likely next: Further preclinical development, IND‑enabling studies, and eventual submission for regulatory review, with potential scaling of cell‑culture production.
VaxThera S.A.S. and Codagenix announced a partnership to advance Syn17D‑YF, a fully synthetic yellow fever vaccine candidate designed for modern cell‑culture manufacturing. The collaboration leverages Codagenix’s synthetic‑biology platform to accelerate preclinical work on a vaccine that could be produced at scale without reliance on egg‑based methods. This marks a notable step toward improving global yellow fever vaccine supply and outbreak response readiness.
What's next — scenarios
Base: IND‑enabling studies progress (55%)
Syn17D‑YF moves toward IND filing in late 2027, keeping the partnership on track for clinical trials.
- Completion of preclinical toxicity studies
- Positive immunogenicity data in animal models
- Regulatory feedback on CMC section
Upside: Fast‑track approval and large orders (30%)
Vaccine receives breakthrough designation, leading to early procurement agreements with Gavi and UNICEF.
- Demonstration of >90% seroconversion in Phase 1
- Grant of fast‑track status by FDA/EMA
- Funding commitment from global health agencies
Downside: Development delays (15%)
Unexpected manufacturing challenges push IND submission beyond 2028, straining the partnership timeline.
- Failure to meet cell‑culture yield thresholds
- Identification of stability issues in formulation
- Regulatory request for additional non‑clinical data
Timeline
- — VaxThera and Codagenix Partner to Advance a Next Generation Yellow Fever Vaccine (PR Newswire)